Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Medical Industry Feature

Biosimilar Essentials: Insights on Development, Approval, and Real-World Data

Details
Recommended

Overview

ReachMD Healthcare Image
RestartResume

Join us as we dispel some common myths regarding the development and approval of biosimilars.

  • Sponsored by

  • Overview

    A biosimilar development program is intended to demonstrate biosimilarity, meaning the product is highly similar on a structural and functional level to the reference product and that there are no clinically meaningful differences between the biosimilar and its reference product. But despite that, there are still a lot of myths around the effectiveness of biosimilars. That’s why Dr. Charles Turck speaks with Drs. Carl Awh and Leah Christl about the development and approval of biosimilars along with the findings from a study that focused on anti-VEGF biosimilars. Dr. Awh is a retina specialist in Nashville, Tennessee, and Dr. Christl is the Head of Regulatory Affairs and Regulatory Policy for Biosimilars at Amgen.  


    ©2024 Amgen Inc. All rights reserved. USA-OCF-82474 5/24

Schedule13 Dec 2024